At a Glance
20 mg
Once daily
−56–59%
LDL-C vs placebo
1st
Oral PCSK9i
None
Contraindications
- Generic: enlicitide (as enlicitide decanoate; development code MK-0616) — a macrocyclic peptide PCSK9 inhibitor.
- First oral agent in its class: prior proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors were injectable antibodies or small-interfering RNA.
- Indication: adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
Mechanism
Class: oral PCSK9 inhibitor
Structure: macrocyclic peptide
Target: free plasma PCSK9
PCSK9 (proprotein convertase subtilisin kexin type 9) binds low-density lipoprotein receptors (LDLRs) on liver cells and drives their degradation. Enlicitide binds PCSK9 and blocks that interaction, so more LDLRs remain available to clear LDL-C — lowering circulating LDL-C. Single doses ≥10 mg reduce free PCSK9 by >90%; steady state is reached in ~7 days, and the LDL-C effect is measurable as early as 4 weeks.
Dosing & Administration
One 20 mg tablet by mouth, once daily
Take on an empty stomach in the morning with water, black coffee, or plain tea. Swallow whole — do not split, crush, or chew. Wait at least 30 minutes before eating or drinking anything other than water, black coffee, or plain tea.
- Missed dose: take as soon as possible, at least 30 minutes before the next food or drink (other than water/black coffee/plain tea). Do not take two doses in one day.
- Monitoring: assess LDL-C when clinically appropriate; the effect can be seen by ~4 weeks.
- May be taken with other medications; can be taken with black coffee or plain tea without meaningful change in exposure.
Pharmacist pearl — food timing is not optional. The tablet uses a sodium-caprate permeation enhancer to achieve oral absorption (bioavailability is only ~1%). Taking it within 30 minutes after a meal lowered exposure (AUC/Cmax) by roughly 48–50%. Counsel the empty-stomach, morning, 30-minute rule explicitly — adherence to timing drives efficacy.
Efficacy (primary endpoint: % change in LDL-C at week 24 vs placebo)
| Trial | Population (n) | LDL-C vs placebo | Non-HDL-C | ApoB |
|---|---|---|---|---|
| Trial 1 — CORALreef Lipids | Hypercholesterolemia + ASCVD or high risk, on statins (n=2,904) | −56% | −53% | −50% |
| Trial 2 — CORALreef HeFH | Heterozygous familial hypercholesterolemia, on statins (n=303) | −59% | −53% | −49% |
Both trials 52-week, double-blind, randomized, placebo-controlled, in patients needing further LDL-C lowering despite moderate/high-intensity statins; primary endpoint difference vs placebo at week 24, p<0.001. (ASCVD = atherosclerotic cardiovascular disease; ApoB = apolipoprotein B.) Treatment arms: Trial 1 Lipfendra −57% vs placebo +3%; Trial 2 −58% vs +3%.
Cardiovascular Outcomes — Read the Label Carefully
Approval rests on LDL-C lowering (a surrogate endpoint) — the primary outcome in both trials was percent change in LDL-C at week 24, not a cardiovascular event endpoint. The label's statement that lowering LDL-C reduces major adverse cardiovascular events (MACE) reflects the established class-level relationship demonstrated with statins and antibody PCSK9 inhibitors — not a completed cardiovascular-outcomes trial of enlicitide itself. Position it as a potent LDL-lowering option; dedicated enlicitide outcomes evidence is not part of the current labeling.
Safety & Specific Populations
Adverse reactions
- Overall frequencies similar to placebo. Most common in the HeFH trial: diarrhea (7% vs 2%) and dizziness (9% vs 4%).
- No contraindications. No clinically significant QTc prolongation at 4× the maximum-dose Cmax.
Specific populations
- Pregnancy: discontinue when pregnancy is recognized unless benefits outweigh risks — potential fetal harm based on mechanism (cholesterol is needed for fetal development). Insufficient human data; no embryofetal harm in animals at 58-fold (rat) / 51-fold (rabbit) human exposure, but enlicitide crosses the placenta (3–5% of maternal plasma). Lactation: no human data; in rats, pup plasma was ≤0.7% of maternal — weigh the benefits of breastfeeding against maternal need.
- Renal: exposure rises 5% / 11% / 26% in mild / moderate / severe impairment, and 17% / 75% in end-stage disease dosed before / after hemodialysis — none clinically meaningful. No dose adjustment.
- Hepatic: unaffected by moderate impairment (Child-Pugh B); severe (C) not studied. Geriatric: 45% of trial patients were ≥65 and 12% ≥75 — no overall difference in safety or effectiveness. Pediatric: not established.
Drug Interactions — a Clean Profile
- No clinically meaningful drug interactions identified; very low potential via cytochrome P450 enzymes or drug transporters at the therapeutic dose.
- Did not affect exposure of warfarin, digoxin, levothyroxine, lithium, atorvastatin, lisinopril, alendronate, or oral semaglutide.
- Atorvastatin and oral semaglutide did not affect enlicitide exposure.
Notable versus many oral agents: no anticoagulant, antidiabetic, or thyroid-replacement interaction signal to manage.
Place in Therapy — the Lipid-Lowering Landscape
Guideline-based care starts with a high-intensity statin; ezetimibe is the usual first oral add-on; when low-density lipoprotein cholesterol (LDL-C) stays above goal, a PCSK9 inhibitor (or bempedoic acid, or inclisiran) is layered on. Enlicitide enters this last step as the first oral PCSK9 inhibitor — matching antibody-level LDL lowering in a once-daily pill.
| Class / agent | Route & frequency | ~LDL-C lowering | CV outcomes |
|---|---|---|---|
| Statin (high-intensity) | Oral, daily | ~50% | Proven — foundation of therapy |
| Ezetimibe | Oral, daily | ~15–25% (add-on) | Modest benefit (IMPROVE-IT) |
| Bempedoic acid | Oral, daily | ~15–25% (add-on) | Proven (CLEAR Outcomes) |
| PCSK9 antibody — evolocumab / alirocumab | Subcutaneous, every 2–4 weeks | ~50–60% | Proven (FOURIER; ODYSSEY OUTCOMES) |
| Inclisiran (siRNA) | Subcutaneous, twice yearly (after loading) | ~50% | Pending (ORION-4 / VICTORION) |
| Enlicitide (Lipfendra) | Oral, daily | ~56–59% | Pending (CORALreef Outcomes, ~2029) |
- Same target, oral route. Enlicitide's LDL lowering is on par with the injectable PCSK9 antibodies and numerically above the siRNA inclisiran — delivered as a once-daily tablet. Its defining advantage is access and adherence for patients who can't or won't inject.
- Where it slots in: add-on when a statin ± ezetimibe leaves LDL-C above goal — the same rung as injectable PCSK9 inhibitors, bempedoic acid, or inclisiran. In the head-to-head CORALreef AddOn trial, enlicitide lowered LDL-C ~65% on a statin background — greater than ezetimibe (~28%), bempedoic acid, or the two combined (~37%).
- The outcomes caveat that drives selection: the PCSK9 antibodies (and bempedoic acid) have completed, positive cardiovascular-outcomes trials; enlicitide's — CORALreef Outcomes, >14,500 patients — runs through ~2029. Until it reports, enlicitide is chosen on LDL efficacy plus oral convenience, not on its own event data. Where an outcomes-proven agent would otherwise serve, that trade-off is worth weighing explicitly.
- Cost (news-reported, not from the label): a list price of roughly $300/month has been reported versus ~$500 for injectable PCSK9 antibodies — verify actual coverage and patient cost with the payer.
Patient Information — Plain Language
Lipfendra is a once-a-day pill that lowers "bad" cholesterol (LDL). It works the same way as the PCSK9 cholesterol shots, but it's the first one you can take as a tablet instead of an injection. It's meant to be used along with a healthy diet, exercise, and usually a statin.
How to take it:
- Take one tablet each morning on an empty stomach with water, black coffee, or plain tea.
- Wait at least 30 minutes before eating or drinking anything else — this really matters for the medicine to work.
- Swallow it whole; don't split, crush, or chew. Keep it in its original bottle with the desiccant, tightly closed.
- Missed a dose? Take it as soon as you can (at least 30 minutes before food/other drinks). Never take two in one day.
What to watch for: the most common effects are diarrhea and dizziness. Tell your clinician if you are pregnant, planning pregnancy, or breastfeeding.
Source & Reference
FDA / MERCKLipfendra (enlicitide) Prescribing Information — revised 7/2026
merck.com/product/usa/pi_circulars/l/lipfendra/lipfendra_pi.pdf
TRIALSCORALreef Lipids (NCT05952856) · CORALreef HeFH (NCT05952869) · CORALreef AddOn (NCT06450366) · CORALreef Outcomes, ongoing (NCT06008756)
clinicaltrials.gov — tap a trial ID above